吉西他滨联合奈达铂治疗晚期肺鳞癌的近期疗效观察

目的比较吉西他滨分别联合奈达铂、顺铂对初治晚期肺鳞癌的近期临床疗效及不良反应情况。方法80例晚期肺鳞癌病人随机分为观察组和对照组，各40例。观察组采用吉西他滨联合奈达铂进行治疗，对照组采用吉西他滨联合顺铂治疗，共2个周期，后按RECIST1.1评价标准，评估其近期疗效、不良反应及对凝血功能的影响。结果2组近期疗效比较差异有统计学意义（P < 0.05）。2组病人在血液学毒性方面，白细胞计数、中性粒细胞、血红蛋白、血小板计数化疗前后比较均无统计学意义（P>0.05）；在非血液学毒性方面，包括胃肠道反应（恶心、呕吐等）、肝功能损害等化疗前后比较均无统计学意义（P>0.05）；2组病人化疗后D-二聚体均较化疗前升高，观察组增高更明显，但差异无统计学意义（P>0.05）。结论吉西他滨联合奈达铂用于晚期肺鳞癌病人较吉西他滨联合顺铂短期疗效好，不良反应及对D-二聚体影响小。

Short-term efficacy observation of gemcitabine combined with nedaplatin in the treatment of advanced lung squamous cell carcinoma

ObjectiveTo compare the short-term clinical efficacy and adverse reactions between gemcitabine combined with nedaplatin and cisplatin in the treatment of advanced lung squamous cell carcinoma.MethodsEighty patients with advanced lung squamous cell carcinoma were randomly divided into the observation group and control group(40 cases in each group).The observation group was treated with gemcitabine combined with nedaplatin, and the control group was treated with gemcitabine combined with cisplatin for 2 cycles.The short-term efficacy, adverse reactions and influence on coagulation function were evaluated according to RECIST1.1 evaluation criteria.ResultsThe difference of the short-term efficacy between two groups was statistically significant(P < 0.05).In terms of hematological toxicity, there was no statistical significance in the levels of white blood cell, neutrophils, hemoglobin and platelet and PLT between two groups before and after chemotherapy(P>0.05).In terms of non-hematological toxicity, there was no statistical significance in the gastrointestinal reactions(nausea, vomiting, etc.) and liver function damage between two groups before and after chemotherapy(P>0.05).After chemotherapy, the levels of D-dimer in two groups increased compared with that before chemotherapy, the increasing of which in observation group was more obvious, and the difference of which between two groups was not statistically significant(P>0.05).ConclusionsCompared with gemcitabine combined with cisplatin, the application of gemcitabine combined with nedaplatin in patients with advanced lung squamous cell carcinoma has better short-term efficacy, less adverse reactions and influence on D-dimer.